Aegerion Pharmaceuticals, Inc. Announces Interim Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced interim data from its ongoing pivotal Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug. This pivotal trial is designed to evaluate the efficacy, safety and tolerability of lomitapide for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH), a rare and extremely serious condition resulting in severely elevated levels of low-density lipoprotein cholesterol (LDL-C), which leads to life-threatening cardiovascular events. Patients afflicted by this condition face a severely curtailed life expectancy and limited treatment options. Preliminary data from this trial indicate that lomitapide significantly reduced patients’ LDL-C vs. baseline, was well tolerated and demonstrated a promising safety profile, including low levels of hepatic fat accumulation.